| 86.99 Delayed Data As of Sep 13 |  -2.50 / -2.79%Today’s Change | 73.17 Today|||52-Week Range 95.00 | +13.18% Year-to-Date |
| Adverum Reports Data From Phase I Wet AMD Study, Stock Down Sep 13 / Zacks.com - Paid Partner Content | Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe Sep 11 / Zacks.com - Paid Partner Content |
| Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance Sep 12 / Zacks.com - Paid Partner Content | Novartis Announces Positive Long-Term Data on Migraine Drug Sep 09 / Zacks.com - Paid Partner Content |
| J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients Sep 12 / Zacks.com - Paid Partner Content | Pfizer is a Top Drugmaker: Is it the Right Time to Buy It? Sep 06 / Zacks.com - Paid Partner Content |
| Has Novartis (NVS) Outpaced Other Medical Stocks This Year? Sep 12 / Zacks.com - Paid Partner Content | FDA Grants Priority Review to Global Blood's SCD Candidate Sep 06 / Zacks.com - Paid Partner Content |
| 4 Big Drugmakers Boasting Impressive Oncology Pipelines Sep 11 / Zacks.com - Paid Partner Content | Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA Sep 06 / Zacks.com - Paid Partner Content |
| Previous close | 89.49 |
| Today’s open | 87.65 |
| Day’s range | 86.90 - 87.84 |
| Volume | 2,523,338 |
| Average volume (3 months) | 1,959,300 |
| Market cap | $199.3B |
| Earnings growth (last year) | +65.34% |
| Earnings growth (this year) | +11.49% |
| Earnings growth (next 5 years) | +9.00% |
| Revenue growth (last year) | +5.41% |
| P/E ratio | 29.5 |
| Price/Sales | 3.87 |
| Price/Book | 2.56 |
| Today’s change | Today’s % change | |
|---|---|---|
| PFEPfizer | -0.37 | -0.99% |
| MRKMerck | -0.15 | -0.18% |
| AZNAstraZeneca | -0.13 | -0.30% |
| LLYEli Lilly and Co | -0.58 | -0.52% |
| Next reporting date | October 22, 2019 |
| EPS forecast (this quarter) | $1.32 |
| Annual revenue (last year) | $52.0B |
| Annual profit (last year) | $12.6B |
| Net profit margin | 24.30% |
Sector Health Technology |
Industry Pharmaceuticals: Major |
Chief Executive Officer Vasant Narasimhan |
Chief Financial Officer Harry Werner Kirsch |
Corporate headquarters Basel, Basel-stadt (basle Town) |
